Launch of the production complex on area of 2,500 m2
First production line (prokaryotic) is prepared for the production of the first batch
Registered the first product (interferon substance)
Launch of the second production line (eukaryotic)
Start of production of the first finished dosage form (Altevir)
Signing of the cooperation agreement with Center of Genetic Engineering and Biotechnology of Cuba
Opening of R&D center on area of 1000 sq m
First product registered (Interferon substance)
Launch of an additional production plant on area of 1000 sq m
Walvax cooperation agreement signed
Monoclonal Antibodies production line prepared and launched
Beginning of cooperation with BIO-THERA (China) on localization and registration of medical drugs: GOLIMUMAB and USTEKINUMAB
Participation in the development of a scalable industrial technology for the production of the Sputnik V vaccine
Cooperation agreement signed with Prestige Biopharma (South Korea)
Mabxience S.A. signed an agreement on localization of Rituximab